Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan intervention for end point reduction in hypertension study

Hypertension

Volumn 47, Issue 5, 2006, Pages 868-873

  Narayan, Puneet ^a   Papademetriou, Vasilios ^a   Wachtell, Kristian ^b,c   Gerdts, Eva ^d   Boman, Kurt ^e   Nieminen, Markku S ^f   De Simone, Giovanni ⁱ   Dahlöf, Björn ^g   Fyhrquist, Frej ⁱ   Hoieggen, Aud ^h   Devereux, Richard B ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e Skellefteå Hospital   (Sweden)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ Veterans Administration Medical Center ^*

Author keywords

Echocardiography; Hemoglobin; Hypertension

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; LOSARTAN; OXYGEN; ANTIHYPERTENSIVE AGENT;

A WAVE; ADULT; AGED; ARTICLE; BODY MASS; CALCULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DECELERATION; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOGRAPHY; ELECTROCARDIOGRAM; ENDOCARDIUM; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAXATION TIME; VASCULAR RESISTANCE; BLOOD; BLOOD FLOW VELOCITY; ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART CONTRACTION; METABOLISM; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; CARDIAC OUTPUT; ECHOCARDIOGRAPHY; FEMALE; HEMOGLOBINS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; MITRAL VALVE; MULTIVARIATE ANALYSIS; MYOCARDIAL CONTRACTION; OSMOLAR CONCENTRATION; SEX CHARACTERISTICS; VENTRICULAR FUNCTION, LEFT;

EID: 33646164181     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000215578.40687.6f     Document Type: Article

References (34)

1. Poiseiulle JLM. Mémoirés présentés par divers savants á l'academie royale des sciences de l'institute de France. 1846;9:433.
2. Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J. 1993;14:597-601.
3. Klein W, Eber B, Dusleag J, Gasser R, Fruhwald FM, Schumacher M, Zweiker R, Stoschitzky K. Hypertension and hemorheology. Wien Med Wochenschr. 1995;145:355-357.
4. Simpson LO. Blood pressure and blood viscosity. N Z Med J. 1988;101:581.
5. London M. The role of blood rheology in regulating blood pressure. Clin Hemorheol Microcirc. 1997;17:93-106.
6. Koenig W, Sund M, Ernst E, Matrai A, Keil U, Rosenthal J. Is increased plasma viscosity a risk factor for high blood pressure? Angiology. 1989;40:153-163.
7. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med. 1981;70:1195-1202.
8. Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, Kaul S. Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation. 2001;104:2704-2709.
9. Gobel BO, Schulte-Gobel A, Weisser B, Glanzer K, Vetter H, Dusing R. Arterial blood pressure. Correlation with erythrocyte count, hematocrit, and hemoglobin concentration. Am J Hypertens. 1991;4:14-19.
10. Fossum E, Hoieggen A, Moan A, Nordby G, Velund TL, Kjeldsen SE. Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors. Blood Press. 1997;6:161-165.
11. Folkow B. The fourth Volhard lecture: cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med. 1978;4(suppl):3s-22s.
12. Ruiz L, Penaloza D. Altitude and hypertension. Mayo Clin Proc. 1977;52:442-445.
13. Sunder-Plassmann G, Horl WH. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis. 2001;38(4 Suppl 1):S20-S25.
14. Devereux RB, Drayer JI, Chien S, Pickering TG, Letcher RL, DeYoung JL, Sealey JE, Laragh JH. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol. 1984;54:592-595.
15. de Simone G, Devereux RB, Roman MJ, Ganau A, Chien S, Alderman MH, Atlas S, Laragh JH. Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in normal adults. Am J Cardiol. 1991;68:1704-1708.
16. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention for Endpoint Reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705-713.
17. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32:989-997.
18. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
19. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Smith G, Dahlöf B. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press. 2001;10:74-82.
20. Bella JN, Wachtell K, Palmieri V, Liebson PR, Gerdts E, Ylitalo A, Koren MJ, Pedersen OL, Rokkedal J, Dahlöf B, Roman MJ, Devereux RB. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention for Endpoint Reduction in Hypertension Study. J Hypertens. 2001;19:127-134.
21. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Dahlöf B. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction in Hypertension. J Hypertens. 2000;18:1129-1138.
22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik J. Recommendations for quantitation of the left ventricle by 2-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
24. Gutgesell HP, Paquet M, Duff DF, McNamara DG. Evaluation of left ventricular size and function by echocardiography. Results in normal children. Circulation. 1977;56:457-462.
25. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7-11.
26. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
27. Devereux RB, Dahlöf B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:61-65.
28. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451. (Correction 1994;24:844.)
29. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J. 1990;120:116-123.
30. Ganong WF. Review of Medical Physiology. Tenth Edition. New York, NY: Lange Medical Publications;1981:521.
31. Giannattasio C, Piperno A, Failla M, Vergani A, Mancia G. Effects of hematocrit changes on flow-mediated and metabolic vasodilation in humans. Hypertension. 2002;40:74-77.
32. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yeh JL, Fabsitz RR, Howard BV. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation. 1997;96:1416-1423.
33. Devereux RB, Chinali M, Liu JE, Roman MJ, Best LG, Galloway JM, Lee ET, de Simone G, Howard BV. Association of fat-free mass with hypertension: The Strong Heart Study. Circulation. 2003;108(Suppl-IV):IV-631.
34. Sasagawa I, Nakada T, Hashimoto T, Kubota Y, Suzuki H, Sawamura T. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. Int Urol Nephrol. 1994;26:237-243.